News headlines about Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) have been trending positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetralogic Pharmaceuticals Corp earned a coverage optimism score of 0.37 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.0364803184669 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Tetralogic Pharmaceuticals Corp (NASDAQ TLOG) opened at 0.0225 on Friday. Tetralogic Pharmaceuticals Corp has a 52 week low of $0.02 and a 52 week high of $0.30. The firm has a 50-day moving average of $0.02 and a 200 day moving average of $0.04. The company’s market cap is $557302.50.

WARNING: This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/tetralogic-pharmaceuticals-corp-tlog-receiving-favorable-press-coverage-accern-reports.html.

About Tetralogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.